26.5 C
Vientiane
Sunday, September 14, 2025
spot_img
Home Blog Page 744

French Cream: The Secret Ingredient to Perfect Desserts and Culinary Excellence

Renowned for its richness, purity, and versatility, French cream remains the preferred choice of chefs and culinary artisans worldwide.

SINGAPORE, May 26, 2025 /PRNewswire/ — From the lush pastures of Normandy to the culinary capital of Paris, French cream has long held a place at the heart of fine cuisine. Celebrated for its exceptional quality, smooth texture, and rich flavor, it reflects generations of savoir-faire, a blend of tradition, terroir, and expert craftsmanship.

Produced under strict quality standards and sourced from pasture-raised cows, French cream offers a naturally velvety consistency and a high butterfat content, lending depth and elegance to both sweet and savory creations. Whether whipped into airy peaks for pastries, folded into classic French sauces, or used in iconic dishes like crème brûlée, it delivers unmatched versatility and consistency.

“French cream is not just an ingredient—it’s an expression of craftsmanship and culinary heritage,” says Emilie Martin, Managing Director APAC, CNIEL. “Its unique qualities make it an essential element in kitchens around the world, from Michelin-starred restaurants to passionate home bakers.”

Celebrating Three Years of Culinary Collaboration in Singapore

Over the past three years, the French cream campaign run by CNIEL and co-funded by the European Union, has proudly partnered with some of Singapore’s most celebrated chefs to highlight its excellence and adaptability. Through culinary workshops, tasting sessions, and masterclasses, these chefs have demonstrated how French cream elevates both traditional French desserts and inventive Asian-inspired dishes.

As Chef Cheryl Koh of Les Amis shared, “I only work with French cream, for its flavor, texture, and color. I use liquid cream, fresh cream, and fleurette cream. It has a fresh and pleasant flavor, whips beautifully, and has a wonderful texture.”

French cream has long been the heart of dessert-making, blending flavor and texture to add elegance and richness to every bite. says Chef Alicia, Nesuto

Savoring Singapore: A Culinary Adventure

In 2025, Singapore continues to celebrate French cream through a series of dynamic, hands-on events bringing together professionals, aspiring chefs, and food lovers.

The 3rd Rising Pastry Award: A Celebration of Tomorrow’s Stars

On May 15th, 2025, At-Sunrice Global Chef Academy hosted the 3rd edition of the Rising Pastry Award, a prestigious competition designed to spotlight the region’s most promising young pastry chefs and home bakers. This year’s winner earned a once-in-a-lifetime opportunity to attend a five-day pastry course at the esteemed École Ducasse in France, alongside other ASEAN finalists.

A distinguished panel of judges—including Chef Alicia Wong (Nesuto), Chef Alice Hsiao (Tarte), Chef Kelly (The Prestine, Hyatt), Chef Cindy Khoo (Hyatt), and Chef Frank (At-Sunrice)—evaluated the finalists and awarded the grand prize to Stacy Kwek (@sk.staceyyy), whose inventive creation showcased the elegance and versatility of French cream.

“Competing in the Rising Pastry Chef competition was an incredible first experience that pushed me out of my comfort zone and helped me grow under pressure. I gained valuable insights, made new friends, and learned from other talented chefs. I’m truly grateful for the opportunity, the support, and the positive feedback that boosted my confidence”, the winner said.

Reflections from Past Winners

Last year’s winner, Casey, shared:

“The experience in France was unforgettable. Exploring pastry shops, tasting unique combinations of local fruits and French cream, and attending MOF-led classes at École Ducasse taught me invaluable techniques and deepened my pastry knowledge.”

The Year 1 winner, Kirsten, also reflected fondly on her journey:

“Joining this competition back in 2023 was unexpected. I was blessed to win and enjoy a memorable week at Ferrandi School in Paris. I appreciate it immensely. A big thank you to the team for organizing such a great event.”

What’s Next for French Cream in 2025

The campaign continues with a rich calendar of events:

  • Student Workshops: Future pastry talents will participate in hands-on workshops at ITE Culinary School and At-Sunrice Global Chef Academy with Chef Cheryl Koh from Les Amis, who will mentor aspiring young chefs in advanced pastry techniques using French cream.
  • Trade Demonstrations: Chef Alicia Wong (Nesuto) will headline an exclusive industry event, exploring French cream’s creative potential in modern desserts.
  • Media Gatherings: Influencers and journalists will be invited to an exclusive tasting experience, an intimate celebration of French elegance and culinary artistry.

The Recipe – Introducing the Exclusive Pandan Gateau Basque by Chef Alicia, Nesuto

In this exclusive creation to celebrate Singapore’s 60th anniversary, Chef Alicia pays tribute to heritage through innovation. Known for her refined technique and cultural sensitivity, she shares the inspiration behind her latest dessert, a Pandan Gâteau Basque: “In my kitchen, I’m drawn to infusion—a method that draws out delicate flavors and transforms them into new textures. For this recipe, I wanted to highlight pandan, a Southeast Asian staple often seen in heritage sweets. Inspired by familiar local treats like egg tarts and refined by French pastry techniques, I created a Pandan Gâteau Basque with a touch of rose—nostalgic yet intentional, honoring tradition through a contemporary lens.”

For the video recipe and expert tips directly from Chef Alicia, visit https://www.creamessential.com/sg and start creating your own exquisite Pandan Gateau Basque today.

Gateau Basque
Gateau Basque

Gateaux Basque Dough 

Ingredients: 

  • Whole eggs – 50g 
  • Egg yolks – 20g 
  • Icing sugar – 200g 
  • Salt – 1.5g 
  • Plain flour – 560g 
  • Chilled cubed butter – 280g 
  • Whipping cream – 80g 

Instructions: 

1. Chill Ingredients: 

  • Chill the butter, plain flour, and icing sugar in the fridge. 

2. Mix Wet Ingredients: 

  • In a bowl, whisk together the whole eggs, egg yolks, whipping cream, and salt. Set aside. 

3. Make Dough Base: 

  • In a food processor, combine the chilled butter, plain flour, and icing sugar. Pulse until the mixture resembles coarse crumbs. 

4. Combine Wet and Dry: 

  • Add the egg mixture to the dough base and mix in a stand mixer until combined. 

5. French “Frassage” Method: 

  • Turn the dough onto a work surface. Gently work it with your hands using the “frassage” method until smooth. 

6. Chill Dough: 

  • Wrap the dough in plastic wrap and refrigerate for 1–2 hours. 

7. Roll and Line Tart: 

  • After chilling, roll the dough to your desired thickness. Line the tart ring with the dough and refrigerate while preparing the custard. 

Gateaux Basque Custard 

Ingredients: 

  • Salt – 1.2g 
  • Milk – 400g 
  • Cream – 320g 
  • Sugar – 72g 
  • Cornstarch – 32g 
  • Plain flour – 28g 
  • Egg yolks – 48g 
  • Pandan leaves – 40g 

Instructions: 

1. Infuse Milk and Cream: 

  • Cut the pandan leaves and combine them with milk, cream, and salt. Vacuum pack the mixture and place it in a water bath at 60°C for 30 minutes. 

2. Blend and Strain: 

  • After 30 minutes, blend the mixture using a hand blender. Fine-strain it into a pot and add 50% of the sugar. 

3. Prepare Egg Mixture: 

  • In a bowl, whisk together the cornstarch, plain flour, egg yolks, and remaining 50% of the sugar. Set aside. 

4. Temper Eggs: 

  • Bring the infused milk mixture to a simmer. Gradually temper it into the egg mixture, then return to the pot. 

5. Cook Custard: 

  • Cook over medium heat, whisking constantly, until the custard thickens. 

6. Cool Custard: 

  • Pour the custard onto a tray and allow it to cool completely. 

Final Assembly 

1. Fill Tart Shell: 

  • Fill the chilled tart shell with the cooled custard, smoothing the top. 

2. Top with Dough: 

  • Roll out the remaining dough and place it on top of the custard. Seal the edges. 

3. Egg Wash and Design: 

  • Brush the top with egg wash and create a design using a fork or pick. 

4. Chill and Bake: 

  • Chill the assembled gateaux in the fridge for 2–3 hours. Preheat the oven to 170°C and bake until golden brown. 

To discover more recipes with French cream by renowned chefs accross Asia please go to the CREAM ESSENTIAL website https://www.creamessential.com/sg

#EuropeanCream #FrenchCream #HolidayDesserts #EnjoyItsFromEurope #FrenchCreamSg @creamessentials_sg

World’s First — XellSmart’s Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial

SUZHOU, China, May 26, 2025 /PRNewswire/ — In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy has received official approval from both China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) for a Phase I clinical trial, to treat spinal cord injury (SCI)  a severe and currently untreatable disease of the central nervous system, affecting more than 15 million patients globally.

As the first regenerative clinical trial globally employing a subtype-specific neural progenitor cell therapeutic product to treat spinal cord injury, the study will be led by the Third Affiliated Hospital of Sun Yat-sen University, a nationally recognized leader in spinal cord injury treatment.

Spinal cord injury (SCI) is a globally prevalent neurological disorder. It represents a critical unmet clinical need, marked by a high rate of disability, irreversibility, early onset, and a significant burden on patients, families, and society. SCI primarily affects young and middle-aged adults, typically resulting from traffic accidents, sports injuries, or other traumas. As a condition that deeply affects a patient’s social function, it requires lifelong care and rehabilitation, leading to a significant economic burden and heavy societal costs. Beyond physical disability, SCI patients often face severe challenges in employment, social integration, and mental health. In high-income countries, lifetime healthcare and caregiving costs per patient may exceed USD 1 million, placing a heavy strain on both families and public health systems.

Worldwide, over 15 million people are estimated to suffer from spinal cord injury (SCI). This figure includes over 3 million patients in China and 300,000 patients in the US. Each year, China and the US report approximately 100,000 and 18,000 new cases of acute or subacute SCI — equivalent to nearly 10 and 2 new cases every hour, respectively.

SCI often leads to partial or complete paralysis, with the loss of motor and sensory function. Most patients experience permanent disability, severely compromising their quality of life. Due to the limited regenerative capacity of the central nervous system, nerve repair following SCI remains extremely challenging. Current treatments are largely limited to rehabilitation and supportive care, with no effective therapies available to promote neural regeneration during the injury phase.

Following over four years of rigorous development and preclinical studies, XellSmart has partnered with leading clinical experts in spinal cord injury to initiate the world’s first registrational clinical trial of an off-the-shelf, allogeneic, iPSC-derived, subtype-specific, regenerative neural cell therapy for spinal cord injury. This pioneering trial represents a landmark achievement in the global effort to develop regenerative therapies for spinal cord injury. Committed to advancing breakthrough treatments, XellSmart aims to redefine possibilities for SCI recovery — bringing a new hope to patients in China and around the world, and delivering tangible relief to families and communities affected by this devastating condition.

For funding and BD cooperation, contact: BD@xellsmart.com 

XellSmart has been dedicated to the development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. Up until now, XellSmart has secured formal approvals from both China’s NMPA and the U.S. FDA for seven registered and registrational clinical trials spanning China and the United States, for iPSC-derived cell therapies to treat CNS diseases  including Parkinson’s disease (Approved Phase I in both China and US), amyotrophic lateral sclerosis (ALS; Approved Phase I in both China and US; Global orphan drug designation by FDA), and spinal cord injury (SCI; Approved Phase I in both China and US), hence pioneering breakthrough advancements in tackling major and severe CNS diseases:

In 2023, China’s first iPSC-derived cell therapy (XS228 injection), developed by XellSmart, received FDA approval and was granted global orphan drug designation (ODD).

In 2024, China’s first national-level registered clinical study of iPSC-derived cell therapy for neurological diseases was approved to treat Parkinson’s disease patients—including China’s first case. More than 12 months of follow-up demonstrated good safety and significant improvements in “off” time, MDS-UPDRS scores, and multiple non-motor symptoms.

In 2024, the world’s first national-level registered clinical study of iPSC-derived cells (XS228 injection) for amyotrophic lateral sclerosis (ALS) was approved. Multiple ALS patients including the world’s first case were treated safely, with preliminary data showing effective slowing of disease progression.

In 2025, China’s first allogeneic off-the-shelf iPSC-derived dopaminergic neural progenitor cell (XS411 injection) registrational Phase I clinical trial was launched, led by the National Neurological Disease Medical Center at Beijing Tiantan Hospital, targeting Parkinson’s disease — the world’s second most common neurodegenerative disorder.

In 2025, China’s first randomized, double-blind controlled registrational Phase I/II clinical trial was launched, led by Huashan Hospital affiliated with Fudan University (also a National Neurological Disease Medical Center), targeting early-onset Parkinson’s disease (EOPD).

In 2025, the world’s first registrational Phase I/II clinical trial of an allogeneic off-the-shelf iPSC-derived subtype-specific neural progenitor cell therapy (XS228 injection) was launched by Peking University Third Hospital, targeting amyotrophic lateral sclerosis (ALS), one of the world’s four major incurable diseases.

In 2025, the world’s first registrational Phase I clinical trial of an allogeneic off-the-shelf iPSC-derived subtype-specific neural progenitor cell therapy was initiated by the Third Affiliated Hospital of Sun Yat-sen University, targeting spinal cord injury (SCI), a major neurological disease.

XellSmart has established a fully dedicated, internationally competitive “All-In” team focusing on development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. XellSmart has built a portfolio of proprietary, globally leading industrial technologies and platforms, fueling sustained in-house innovation centered on its core business. XellSmart has independently built and operates a R&D center, a B+A-grade GMP manufacturing facility and a quality control center with a total area exceeding 5000m2.

Multiple clinical-grade iPSC-derived cell therapy candidates developed by XellSmart have completed core CMC development, with fully integrated clinical-grade manufacturing processes and quality control systems in place. XellSmart has successfully produced clinical batches of multiple GMP-grade iPSC-derived subtype-specific neural progenitor cell therapies, currently deployed in multiple national, registered or registrational clinical studies and global clinical trials.

XellSmart has secured multiple rounds of financing, collectively led by renowned market-driven venture capital firms including Qiming Venture Partners, Eli Lilly Asia Ventures, Sequoia Capital China (Hongshan), and others.

For funding and BD cooperation, contact: BD@xellsmart.com 

Industry Forums at 137th Canton Fair Spotlight Emerging Trends and Global Strategies

GUANGZHOU, China, May 26, 2025 /PRNewswire/ — The 137th China Import and Export Fair (Canton Fair) hosted a series of high-level industry forums, bringing together government officials, financial institutions, business leaders, and subject matter experts. These sessions explored evolving global trade dynamics and offered strategic guidance to Chinese enterprises pursuing international growth.


A standout session on April 17, titled “The New Ecosystem of AI + Consumer Electronics,” focused on how artificial intelligence is transforming the consumer electronics landscape. Discussions emphasized intelligence, personalization, and contextual innovation as key drivers of the sector’s next wave of growth. Leading voices from companies such as Lianlian Global and iFLYTEK shared insights on leveraging AI to create competitive advantages. The forum also marked the release of a white paper that offered practical strategies across six major product categories. Case studies demonstrated how China’s R&D-led and globally integrated production model reshaped global markets.

On April 23, another pivotal forum addressed brand globalization in the home and construction materials sector. Experts and company leaders shared approaches for strengthening reach in the international market. Professor Dai Yonghong of Shenzhen University emphasized the importance of combining AI with a deep understanding of Chinese market strengths to navigate global trade uncertainties. Shi Zhicheng from the China Quality Certification Center highlighted the need to embed carbon reduction strategies in line with China’s dual carbon goals. Customs expert Zu Xiaomin explained how the AEO (Authorized Economic Operator) system facilitates smoother international expansion for certified enterprises. A roundtable featuring executives from several furnishing companies illustrated a key shift in China’s manufacturing—moving from cost-driven competitiveness to a focus on quality and branding.

Additional forums throughout the 137th Canton Fair explored global opportunities across different sectors. The April 25 forum titled “The Rising Wave of ‘China Chic’ Going Global” examined how Chinese domestic brands are integrating traditional design elements with modern innovation to expand overseas. The Luggage & Bags Industry Transformation Forum on May 1 discussed market upgrades and unveiled WGSN’s 2026 Spring/Summer Accessories Trend Report, while the Sports Industry Innovation Forum on the same day spotlighted technology adoption and global brand-building strategies.

Together, these forums reinforced the Canton Fair’s role as a strategic platform for sharing industry foresight, fostering innovation, and supporting Chinese enterprises in their expansion journey into global markets.

 

Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)

SAN FRANCISCO and SUZHOU, China, May 26, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of a Phase 3 clinical study of mazdutide , a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with overweight or obesity (GLORY-1) have been published in The New England Journal of Medicine (NEJM) with a related editorial [https://www.nejm.org/doi/full/10.1056/NEJMoa2411528]. The first authors of this paper are Professor Linong Ji from Peking University People’s Hospital and Professor Jiang Hongwei from the First Affiliated Hospital of Henan University of Science and Technology. In addition, Professor Linong Ji and Dr. Lei Qian from Innovent Biologics, served as the co-corresponding authors.

This marks the first time that a clinical study of mazdutide, the world’s first dual GCG/GLP-1 receptor agonist submitted for marketing, has been featured in a top-tier, peer-reviewed medical journal. It is also the first time a clinical trial of an innovative metabolic and endocrine therapy developed in China has been published in NEJM, a milestone that highlights China’s growing capabilities in drug development and biotechnology innovation. This publication is expected to contribute to the evolving global clinical guidelines for the treatment of overweight and obesity.

Regarding this groundbreaking new study, Professors Vanita R. Aroda of Harvard Medical School and Brigham and Women’s Hospital, Boston, and Leigh Perreault of the University of Colorado Anschutz Medical Campus jointly commented that the GLORY-1 trial reveals distinct characteristics in the Chinese population compared to Western populations. Specifically, younger individuals in China exhibit metabolic dysfunction at rates comparable to or even exceeding those in older Western populations. The dual GCG/GLP-1 receptor agonist therapy demonstrated not only significant reductions in body weight and BMI but also comprehensive improvements in obesity-associated systemic health risks. Moreover, they emphasized that obesity interventions in China must adopt differentiated strategies tailored to local population features, with a focus on liver health and lipid management. Given the earlier onset of obesity in China and its heavier societal burden, earlier intervention is critical—and yields greater long-term benefits. For emerging obesity therapies, the experts noted that pharmacological treatments are only one component of a broader strategy. They advocated for synergizing drug therapies with public health policies to build a comprehensive prevention and treatment system, addressing the global obesity epidemic more effectively.

Mazdutide is expected to launch in China this year, with anticipated approvals for weight management and glycemic control. Recognized for its superior weight loss efficacy and comprehensive metabolic benefits, mazdutide has been ranked among FIERCE Pharma’s 2025 Top 10 Most Anticipated Drugs.

In the GLORY-1 study, a total of 610 participants with obesity (BMI ≥ 28 kg/m2) or overweight (24 kg/m2 ≤ BMI < 28 kg/m2) with at least one obesity-related comorbidity were enrolled and randomized to receive mazdutide 4 mg, 6 mg, or placebo, administered subcutaneously once weekly for 48 weeks. The co-primary endpoints were the percentage change in body weight from baseline and a weight reduction of ≥5% at week 32.

At baseline, the mean weight was 87.2 kg, and the mean BMI was 31.1 kg/m 2. The study results showed that mazdutide significantly reduced body weight compared to placebo at both 4 mg and 6 mg doses.

Based on the efficacy estimand, the mean percent change from baseline in body weight was −10.97%, −13.38%, and −0.24% at Week 32 and −12.05%, −14.84%, and −0.47% at Week 48 in the mazdutide 4 mg, 6 mg, and placebo groups, respectively. A total of 76.3% of participants in the mazdutide 4 mg group and 84.0% in the mazdutide 6 mg group had a weight reduction of ≥5% at week 32, compared with 10.9% in the placebo group; 37.0% of participants in the mazdutide 4 mg group and 50.6% in the mazdutide 6 mg group had a weight reduction of ≥15% at week 48, compared with 2.1% in the placebo group.

The primary endpoint and all key secondary endpoints of the study showed statistically significant superiority to placebo with p-values < 0.001 (main results as follows).

Efficacy Estimand1

Treatment-policy estimand2

Mazdutide

4 mg (N=203)

Mazdutide

6 mg (N=202)

Placebo

 (N = 205)

Mazdutide

4 mg (N=203)

Mazdutide

6 mg (N=202)

Placebo

 (N = 205)

Co-primary endpoint s  (Week 32)

Percent weight reduction

−10.97%

−13.38%

−0.24%

−10.09%

−12.55%

0.45 %

Achieved a weight reduction ≥5%

76.3 %

84.0 %

10.9 %

73.9 %

82.0 %

10.5 %

Some key secondary endpoints (Week 48)

Percent weight reduction

−12.05%

−14.84%

−0.47%

−11.00%

−14.01%

0.30 %

Achieved a weight reduction ≥5%

73.5 %

82.8 %

11.5 %

71.6 %

81.6 %

10.8 %

Achieved a weight reduction ≥10%

55.2 %

67.9 %

2.9 %

53.5 %

66.7 %

2.6 %

Achieved a weight reduction ≥15%

37.0 %

50.6 %

2.1 %

35.7 %

49.5 %

2.0 %

Waist circumference reduction

−9.48 cm

−10.96 cm

−1.48 cm

−9.12 cm

−10.72 cm

−1.41 cm

 

1.        Efficacy estimand aims to estimate the study treatment effect when participants adhered to the planned treatment regimen.

2.        Treatment policy estimand aims to evaluate the efficacy regardless of intercurrent events (early discontinuation of study treatment and initiation of new anti-obesity medication or bariatric surgery).

Mazdutide also significantly reduced blood pressure, blood lipids (total cholesterol, triglycerides, and low-density lipoprotein cholesterol), serum uric acid, transaminase levels, and other cardiovascular and metabolic indicators.

In addition, mazdutide significantly reduced liver fat content.

  • Among participants with baseline liver fat content ≥ 5%, the mean percent changes in liver fat content from baseline to week 48 were −63.26%, −73.18%, and +8.20% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively;
  • Among participants with baseline liver fat content ≥ 10%, the mean percent change from baseline in liver fat content to week 48 were −65.85%, −80.24%, and −5.27% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively.

Good overall safety and tolerability of mazdutide were reported.

  • The overall safety profile of the mazdutide group was consistent with findings from previous studies of mazdutide and aligned with that of other GLP-1 receptor agonists. The most frequently reported treatment-emergent adverse events included nausea, diarrhea, and vomiting, which were mostly mild or moderate in severity.
  • At Week 48, both the mean change from baseline in heart rate was 2.6 beats per minute in both the mazdutide 4 mg and 6 mg groups. There were no safety signals of increased cardiovascular risk observed throughout the study.

Professor Linong Ji, the Leading Principal Investigator of the Study, Peking University People’s Hospital, stated, “For decades, global obesity management guidelines have predominantly relied on data from Caucasian populations, resulting in limited applicability to Asian demographics. Meanwhile, China’s overweight/obese population exhibits distinct clinical characteristics and therapeutic needs compared to Western populations, necessitating evidence-based weight management strategies specifically tailored for Chinese patients. For most Chinese patients with overweight or obesity, the recommended weight loss target should be 5%-15% reduction maintained over 3-6 months. Moderate-to-severe obesity patients may require more ambitious goals. The GLORY-1 study, conducted in Chinese populations aligned with these targets, demonstrated promising outcomes: mazdutide achieved >15% weight reduction in nearly half of participants, indicating its efficacy across people living with overweight to severe obesity.

Published in The New England Journal of Medicine, the GLORY-1 study not only signifies international recognition of China’s innovative research in endocrine-metabolic disorders but also underscores the pioneering innovation of Chinese biopharmaceutical industry. Mazdutide’s successful development will accelerate domestic enterprises’ strategic presence in obesity management, enabling comprehensive, personalized solutions for China’s overweight/obese population throughout their treatment journey.”

Dr. Lei Qian from Innovent Biologics, stated, “Mazdutide is globally first dual GCG/GLP-1 receptor agonist to be approved soon. The publication of its pivotal study GLORY-1 in The New England Journal of Medicine marks a breakthrough in China’s drug development in endocrine and metabolic diseases. The study provides robust, high-quality clinical evidence for treating overweight and obesity in Chinese adults and will undoubtedly influence future clinical guidelines, diagnostic criteria, and standards of care. This academic achievement also demonstrates the exceptional clinical research capabilities of Chinese investigators and the solid innovative R&D abilities of Innovent. With mazdutide’s imminent approval in China, we look forward to offering an advanced therapeutic option to improve the health and quality of life of individuals living with overweight or obesity. As an innovative pharmaceutical company, Innovent has actively responded to and promoted the goal of ‘Healthy China 2030’ by advancing science-based weight management through strategic collaborations and cutting-edge medical achievements. “

About Obesity

China has the world’s largest population of individuals with overweight or obesity[1], a trend that is likely to rise. Obesity is associated to multiple comorbidities, and is a major contributor to reduced life expectancy and quality of life. In 2019, overweight and obesity accounted for 11.1% of deaths from chronic non-communicable diseases in China, nearly doubling from 5.7% in 1990[2].

Despite the chronic nature of obesity and its need for long-term management, treatment options remain limited. While lifestyle interventions remains the cornerstone of treatment, many patients struggle to achieve or maintain meaningful weight reduction. This underscores the urgent need for safe, effective and sustainable pharmacological interventions.

About Mazdutide (IBI362)

Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity.

Mazdutide currently has two NDAs accepted for review by NMPA, including:

  • For chronic weight management in adults with overweight or obesity;
  • For glycemia control in adults with type 2 diabetes.

Mazdutide is currently being evaluated in six Phase 3 clinical studies, including:

  • GLORY-1: A Phase 3 trial in Chinese participants with overweight or obesity.
  • GLORY-2: A Phase 3 trial in Chinese participants with moderate-to-severe obesity.
  • GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD).
  • DREAMS-1: A Phase 3 trial in treatment-naïve Chinese patients with T2D.
  • DREAMS-2: A Phase 3 trial comparing mazdutide and dulaglutide in Chinese T2D patients with inadequate glycemic control on oral antidiabetic drugs.
  • DREAMS-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese patients with T2D and obesity.

Among these, GLORY-1, DREAMS-1 and DREAMS-2 studies have all met their endpoints, and other studies are currently ongoing.

In addition, several new clinical studies of mazdutide are planned, including:

  • A Phase 3 trial in adolescents with obesity.
  • A Phase 3 trial in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity.
  • New studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF).

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: (1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).

( 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References

[1] Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 373–92.

[2] Institute for Health Metrics and Evaluation. Global Health Data Exchange. GBD results tool. http://ghdx.healthdata.org/gbd-resultstool (accessed Jan 10, 2021).

 

iQOO Neo 10 Debuts with Flagship Dual Chips, Delivering Breakthrough Performance and Industry-Leading Battery Life

DONGGUAN, China, May 26, 2025 /PRNewswire/ — iQOO officially unveils the latest addition to Neo lineup—iQOO Neo 10, featuring a powerful dual-chip setup that redefines performance in its class. With next-level performance powered by a flagship-grade Snapdragon® platform and a cutting-edge Supercomputing Chip, a class-leading combination of a large-capacity battery and FlashCharge technology, and a high-refresh-rate, eyecare display built for gaming, iQOO Neo 10 delivers a one-stop flagship-grade experience for users who demand it all.

The newly released iQOO Neo 10, powered by a dual-chip setup of Snapdragon® 8s Gen 4 Mobile Platform and Supercomputing Chip Q1, delivers an experience beyond expectations.
The newly released iQOO Neo 10, powered by a dual-chip setup of Snapdragon® 8s Gen 4 Mobile Platform and Supercomputing Chip Q1, delivers an experience beyond expectations.

Flagship-Level Dual-Chip Setup Brings Breakthrough Performance

Empowered by Qualcomm’s first all-big-core architecture processor, iQOO Neo 10 unleashes extraordinary performance to its fullest. The latest Snapdragon® 8s Gen 4 Mobile Platform features a flagship-grade CPU, delivering a performance boost of 49% and an energy efficiency improvement of 39% compared to the previous generation, with an AnTuTu Benchmark score of 2426162.(1) iQOO Neo 10 offers stronger performance, lower power consumption, faster responsiveness, and greater stability across the board. Whether users are multitasking or running heavy-duty games, the experience stays smooth, efficient, and consistent. The device also supports up to 16 GB of LPDDR5X Ultra RAM, and with Extended RAM enabled, it can keep up to 52 apps active in the background—ensuring seamless switching and effortless handling of high-frequency, multitasking scenarios.

Setting itself apart in its category, iQOO Neo 10 features a dual-chip setup, equipped with the flagship-grade Supercomputing Chip Q1, delivering an immersive, top-tier gaming experience. Through deep synergy between the Supercomputing Chip Q1 and algorithms, iQOO Neo 10 achieves exceptional image processing, supporting Game Super Resolution and industry-leading Ultra-Low-Latency Frame Interpolation—boosting frame rates to up to 144 FPS. It’s also compatible with major video platforms like YouTube and Netflix, offering ultra-clear visuals that go beyond native resolution. Along with numerous game-specific features, iQOO Neo 10 elevates the gaming experience across multiple dimensions, including priority scheduling, visual display, and complete sensory interaction.

To handle intense usage scenarios, iQOO Neo 10 features iQOO’s largest-ever vapor chamber—the same flagship-grade VC cooling system with a surface area of 7000 mm²,(2) precisely covering key heat sources. This advanced 7K Ultra VC Cooling System ensures sustained, stable performance even during extended gaming or heavy loads, keeping the device cool while helping gamers stay at their peak. Additionally, areas with localized heat sources, such as the front-facing camera, are equipped with Pyrolytic Graphite Sheet to maintain stable and smooth performance during prolonged live streaming or video recording sessions.

Industry-Leading Battery System for Ultra-Long, Stable Endurance

iQOO Neo 10 marks a breakthrough in battery capacity, advancing to an equivalent 7000 mAh for a truly long-lasting power experience. Powered by the Gen 3 Silicon BlueVolt Battery, it delivers reliable, high-performance usage—even in extreme cold conditions as low as -20℃. Thanks to cutting-edge innovations, iQOO Neo 10 breaks industry limits by achieving both high energy density and ultra-fast charging. Its 120W FlashCharge leads the industry in power efficiency, enabling the battery to charge faster—reaching 100% from 0% in just 36 minutes. It’s further enhanced by flagship-level Bypass Charging, which powers the device directly through the charger. This reduces battery heat during charging, enhances safety, and extends overall battery lifespan.

A Next-Gen Flagship Eyecare Display with Upgraded Aesthetics

iQOO Neo 10 takes display technology to new heights. Its 1.5K 144 Hz Eyecare AMOLED Display is engineered for both performance and comfort, offering a truly immersive visual experience. Backed by SGS Five-Star Sunlight Readable Display Certification, iQOO Neo 10 offers peak brightness of up to 2000 nits, ensuring crystal-clear visibility even in intense outdoor light. To further protect eye health, it also adopts 4320 Hz PWM Dimming along with Full-Range DC-Like Dimming, significantly reducing screen flicker and visual fatigue. Whether binge-watching shows, scrolling through short videos, or diving into long gaming sessions, users can enjoy a smooth, vivid, and comfortable viewing experience.

iQOO Neo 10’s flagship-level EyeCare display and lightweight design deliver an impressive visual experience and comfortable grip.
iQOO Neo 10’s flagship-level EyeCare display and lightweight design deliver an impressive visual experience and comfortable grip.

iQOO Neo 10 showcases a design philosophy that is clean, premium, youthful, and beyond expectations. With iQOO’s signature futuristic design language, it evokes a unique sci-fi exploration vibe. The device comes in a range of color options, including the sophisticated gold and the vibrant orange, combining high recognizability with bold self-expression. The lightweight body ensures a comfortable grip, with an overall thickness of 8.09 mm and a weight of just 206g, allowing for effortless use even during extended periods.

Flagship-Worthy Imaging Performance

Equipped with a flagship-level main camera and cutting-edge algorithms, iQOO Neo 10 sets a new standard in mobile photography. The 50 MP Sony IMX882 OIS Camera supports advanced full-pixel autofocus, ensuring fast and precise focus in a variety of complex shooting scenarios. Enhanced by flagship-grade NICE algorithms, it optimizes image depth and color reproduction, making every photo vivid, natural, and breathtakingly detailed. Whether capturing Nautical Blue Urban Night View or professional-grade portraits, iQOO Neo 10 delivers exceptional results with ease.

With its flagship-level main camera and advanced algorithms, iQOO Neo 10 brings every photo to life, making them vivid and natural.
With its flagship-level main camera and advanced algorithms, iQOO Neo 10 brings every photo to life, making them vivid and natural.

Designed for Reliability, Engineered for Efficiency

Built to last, iQOO Neo 10 delivers uncompromising durability and reliability. Its reinforced Durable Comprehensive Cushioning Structure, Shield Glass, and Drop-Resistant Protective Film work in tandem to significantly enhance drop resistance—certified to meet Military-Grade Certification. With an IP65 rating for dust and water resistance, it’s ready to take on everyday splashes and dust with ease, adapting effortlessly to dynamic environments. Built on Funtouch OS 15, the system delivers a 60-Month Smooth Experience with pioneering anti-aging capabilities.

Advanced AI capabilities take efficiency to the next level, empowering users to seamlessly navigate both work and life demands. From intelligent image editing to productivity tools and system interactions, iQOO Neo 10 delivers deep, multi-scenario AI integration—offering a smarter, smoother, and more efficient user experience across the board.

Availability

iQOO Neo 10 will be released in India on May 26, Malaysia on May 29, and Indonesia and Thailand on June 4. United Arab Emirates and Saudi Arabia as of mid-June.

At the same time, iQOO Z10, which is more focused on daily use scenarios and has received widespread praise since its launch in India on April 15, is now also stepping into various markets alongside iQOO Neo 10, offering a differentiated experience for users who value long-lasting performance.

About iQOO

iQOO, a sub-brand of vivo, differentiates itself in performance and Esports experience. iQOO leverages the research, quality assurance and after-sales service expertise of vivo, and follows the brand ethos of I Quest On and On to push boundaries, innovate boldly and share the excitement of exploring future technology. With products offering Esports-standard capabilities, iQOO aims to become the top choice of consumers who are passionate about performance and gaming.

For more information, please visit https://www.iqoo.com/en.

(1)The score data was obtained from iQOO laboratory tests based on AnTuTu Benchmark V10.4. The test device is the 16 GB + 512 GB edition of iQOO Neo 10. The data is for reference only. Actual scores may vary according to different phone memory editions and test environments.

(2)The VC size is based on data from the iQOO laboratory. The actual size may slightly vary due to production batches, processes variations, and measurement methods.

 

Ricoh IM C3010 Wins 2025 Pick Award from Keypoint Intelligence

Award recognises standout performance in productivity, usability, and digital workflow capabilities

TOKYO, May 26, 2025 /PRNewswire/ — The RICOH IM C3010 A3 colour multifunction printer has been named a “Highly Recommended” device and selected for a 2025 BLI Pick Award by Keypoint Intelligence, a leading independent evaluator of document imaging solutions.

The Ricoh IM C3010 earns the 2025 BLI Pick Award from Keypoint Intelligence, recognised for outstanding performance in secure, high-productivity document workflows.
The Ricoh IM C3010 earns the 2025 BLI Pick Award from Keypoint Intelligence, recognised for outstanding performance in secure, high-productivity document workflows.

Engineered with enterprise-grade capabilities, the IM C3010 is built to support modern work environments by offering a powerful, secure and flexible solution that streamlines workflows and enhances productivity. This BLI award acknowledges the device’s exceptional performance, intuitive usability, and advanced document handling.

“Recognition like this reinforces how we’re helping customers respond to the growing need for smarter, more secure ways of working,” said Kei Uesugi, Managing Director of Ricoh Asia Pacific. “The IM C3010 combines strong performance with everyday usability, giving businesses the tools to manage documents more efficiently and adapt with confidence.”

Key Features of the IM C3010

  • Smart Operation Panel: 10.1-inch touchscreen with customisable workflows and one-touch task presets to simplify day-to-day use.
  • Fast, Reliable Performance: Quick first-print-out times and consistent job handling for both short and long runs in busy office environments.
  • Advanced Scanning & OCR: High-speed duplex scanning with accurate text recognition and compact file output for efficient digitisation.
  • Robust Security: Integrated features such as secure print, user authentication and data encryption to help protect sensitive information.
  • Mobile & Cloud Ready: Built-in support for AirPrint, Mopria, and Ricoh Smart Device Connector, plus cloud services via Ricoh Smart Integration.

Powering Smart, Secure Workflows

The IM C3010 excels in high-demand office environments, combining exceptional speed, advanced scanning capabilities and robust security features. Its intuitive Smart Operation Panel, accurate OCR performance, and seamless mobile and cloud integration make it ideally suited for organisations seeking to digitise documents efficiently and manage workflows securely. Designed to adapt to changing workplace needs, the IM C3010 supports scalable, future-ready document management.

-Ends-

About the BLI Pick Awards and Keypoint Intelligence:

The BLI Pick Awards, presented by Keypoint Intelligence, are widely recognised as a mark of excellence in the print and imaging industry. These awards are based on comprehensive hands-on testing and assessment of key performance areas, including reliability, usability, image quality, productivity, and overall value. Only the top-performing devices in each category earn a coveted “Pick”.

Keypoint Intelligence has been a trusted authority in digital imaging for over 60 years, offering independent lab testing, market research and strategic insights to manufacturers, partners and end users. Its evaluations help businesses identify solutions that deliver measurable performance in real-world environments — making a BLI Pick Award a clear signal of product quality and competitive strength.

About Ricoh

Ricoh is a leading provider of integrated digital services and print and imaging solutions designed to support the digital transformation of workplaces, workspaces and optimise business performance.

Headquartered in Tokyo, Ricoh’s global operation reaches customers in approximately 200 countries and regions, supported by cultivated knowledge, technologies, and organisational capabilities nurtured over its 85-year history. In the financial year ended March 2025, Ricoh Group had worldwide sales of 2,527 billion yen (approx. 16.8 billion USD).

It is Ricoh’s mission and vision to empower individuals to find ‘Fulfillment through Work’ by understanding and transforming how people work so we can unleash their potential and creativity to realise a sustainable future.

For further information, please visit www.ricoh.com


###

© 2025 RICOH ASIA PACIFIC PTE LTD. All rights reserved. All referenced product names are the trademarks of their respective companies.

AB Charity Foundation X AB Blockchain Join Forces to Advance the Global “Tech for Good” Mission

DUBLIN, May 26, 2025 /PRNewswire/ — AB Charity Foundation (AB Foundation X AB Blockchain) today announced the addition of 10 internationally influential statespersons and global affairs experts to its Senior Advisory Board, further strengthening its strategic think tank and supporting AB Foundation X AB Blockchain in expanding technology-enabled philanthropy and global collaboration.

Their inclusion means the Foundation’s advisory network now spans five continents and nearly 30 former and sitting heads of state, international organization leaders, and policy experts, forming a cross-cultural, cross-sector, cross-institutional “Global Philanthropy Strategy Engine.”

Bertie Ahern, Chair of the Foundation and former Prime Minister of Ireland, said, “We welcome these visionary and action-oriented advisors to AB. ‘Tech for Good’ is a global cooperative endeavor—only by combining governance expertise with technological innovation can we build a trusted, inclusive, and sustainable global philanthropy ecosystem.”

AB Charity Foundation will continue to broaden its governance network and collaborate with the United Nations system, international NGOs, government agencies, and leading technology firms to drive “verifiable acts of goodwill” in critical areas such as education, healthcare, environmental protection, and humanitarian relief.

New Senior Advisory Board Members:

  • Olusegun Obasanjo — Former President of Nigeria and former Chairperson of the African Union, renowned for driving economic reform and regional cooperation across Africa.
  • Victor Yushchenko — Former President of Ukraine, celebrated economist and reform-minded leader instrumental in the country’s democratic transition.
  • Thomas Axworthy — Distinguished Canadian policy scholar and public administration expert, former Secretary to the Prime Minister (Chief Policy Advisor).
  • Dzhoomart Otorbaev — Former Prime Minister of Kyrgyzstan, noted economist and policymaker, leading reformist in Central Asia.
  • Denzil Douglas — Former Prime Minister and current Minister of Foreign Affairs of Saint Kitts and Nevis.
  • Joanna Nurse — Senior expert at the World Health Organization, with extensive experience in global health policy and public health management.
  • Maha Ibrahim Mohamed Morsy — Wife of former Egyptian Prime Minister Essam Sharaf, active leader in Egypt’s social welfare and education sectors.
  • Kateryna Yushchenko — Wife of Ukraine’s third President Victor Yushchenko; as First Lady she championed healthcare, child welfare, and cultural exchange initiatives.
  • Antonina Stoyanova — Former First Lady of Bulgaria and spouse of ex-President Petar Stoyanov; legal expert and diplomat who served in various United Nations roles.
  • Milena Dobronic — Spouse of former Bolivian President Jorge Quiroga; prominent advocate for social services and education in Bolivia.

About AB Charity Foundation

AB Charity Foundation is an independent international NGO registered in Ireland with EU legal status, supported technologically by AB DAO. The Foundation leverages blockchain, AI, and other cutting-edge technologies to build global philanthropic infrastructure, pioneering a “Governance Trust + Technology-Driven” paradigm to serve the public good.

Currently, $AB is available for trading on over a dozen exchanges, including Bitget, HTX, MEXC, Gate, BingX, BitMart, DigiFinex, Lbank, Hotcoin, Biconomy, BTSE, UEEx, WEEX, and 4E.

Learn more at our official website. https://www.ab.org/en/charityFoundation/

JA Solar with 23 Leading Solar Companies unveils the first Initiative for Global Solar Sustainable Alliance at UNGC’s summit

JAKARTA, Indonesia, May 26, 2025 /PRNewswire/ — On May 25, 2025, at the UN Global Compact (UNGC)’s Inaugural Global Business Summit in Jakarta, a total of 24 global leading solar companies including JA Solar, Jinko Solar, Tongwei, LONGi, GCL Group and other core upstream suppliers, collectively released the initiative for “Global Solar Sustainable Alliance (GSSA)”.

Distinguished leaders across government, industry and academia attended the summit, including United Nations Global Compact Assistant Secretary-General and CEO Sanda Ojiambo, United Nations Resident Coordinator in China Siddharth Chatterjee , Chairman of the National Economic Council of the Republic of Indonesia H.E. Luhut B. Pandjaitan, Founder and co-chairman of Bridgewater Associates Ray Dalio, President of the China Electricity Council Bao’an Xin, Chairman of Xiamen Airlines Dong Zhao, Founder and Chairman of GCL Gongshan Zhu.

At this critical juncture of global energy transition, the solar industry, as a cornerstone of renewable energy, serves as a pivotal solution to combat climate change and achieve carbon neutrality goals. Amid rapid industry growth, leading enterprises have jointly launched this initiative to address social and environmental challenges and advance sustainable development. Committed to delivering clean energy globally, the Initiative aims to strengthen sustainability across the entire value chain — promoting green mineral sourcing from the source, protecting ecosystems and biodiversity, building an equitable society for common good, and driving inclusive growth.

Aligned with the UNGC Ten Principles and Sustainable Development Goals (SDGs), the Initiative outlines 9 actionable pathways across three pillars, advancing ESG progress across the solar value chain and promoting its positive impact on the international market.

The GSSA initiative has garnered strong endorsement from the UNGC. Meng Liu, UNGC China Representative, stated: “We commend the global solar industry, particularly Chinese photovoltaic enterprises, for their contributions to advancing the global energy transition, and we welcome the launch of this initiative. Closely aligned with the principles of the United Nations Global Compact, the Initiative underscores corporate responsibilities in environmental protection, human rights safeguards, and sound governance. We look forward to the solar industry setting an exemplary model for global sustainable development through collective action.”

Jing Li, Vice President of Branding and Sustainability Officer of JA Solar, officially launched this GSSA Initiative at the event, and introduced JA Solar’s newly constructed responsible supply chain strategy with the theme of “Together Towards Tomorrow”, which aims to promote the multi-stakeholders along the industry’s value chain to evolve towards a sustainable future.

UNGC encourages more solar companies and supply chain partners to join this initiative and jointly advance the sustainable development of the industry. To truly fulfill the summit’s vision of ‘Better Business, Better World: Accelerating the SDGs’, the first co-signatories pledge to collaboratively develop a concrete action roadmap with stakeholder engagement, to ensure effective implementation of the Initiative.

A few GSSA representatives advocated for strengthening sustainability across the entire value chain at the summit
A few GSSA representatives advocated for strengthening sustainability across the entire value chain at the summit

Appendix : Global Solar Sustainable Alliance (GSSA)

As the backbone of renewable energy, the global solar sector provides consumers, industries, and society with affordable and reliable clean energy. It has made remarkable contributions to advancing global energy transition and promoting sustainable development, with immense potential yet to be realized.

On the other hand, after decades of growth, the social and environmental footprints of the solar industry, particularly the associated risks across its supply chain—have increasingly emerged. These challenges pose significant obstacles to unleashing the industry’s full potential and achieving its own sustainable development.

In light of this, we, as the undersigned photovoltaic enterprises and supply chain participants, guided by the Ten Principles of the United Nations Global Compact and the UN Sustainable Development Goals (SDGs), hereby launch the Global Solar Sustainable Alliance (GSSA). We call on all companies in the industry and its supply chains to adopt sustainability principles and strategies, and actively undertake the following actions:

I. Just Transition: Safeguarding the green ecosystems and environment

a) Reduce pollution, conserve resources, improve environmental management, implement clean production, and promote a circular economy.

b) Cut energy consumption and carbon emissions, adapt to climate change, establish science-based greenhouse gas reduction targets, and achieve net-zero emissions as soon as possible.

c) Protect biodiversity and ecosystems, promoting green mining from origins of materials, ensuring zero deforestation and no net loss of biodiversity.

II. People-Centric Development: Building an Equitable Society for Common Good

a) Respect and protect workers’ fundamental rights, create gender-responsive, diverse, inclusive, safe, and healthy workplaces, and enhance employees’ skills and development potential.

b) Advance responsible procurement and marketing practices, implement human rights due diligence in supply chains, improve value chain transparency, traceability, and collaborative mechanisms, and strengthen supply chain resilience.

c) Plan PV projects in alignment with local conditions, respect the rights of communities and residents, and leverage industry expertise to support community and social development.

III. Governance Enhancement: Driving Inclusive Growth

a) Optimize corporate governance structures, enhance professionalism and diversity in governance mechanisms, improve investor relations management, and protect the rights of minority shareholders.

b) Operate with integrity and compliance, oppose all forms of unfair competition practices, proactively uphold a sound market order, and foster the healthy development of the industry.

c) Strengthen internal and external oversight systems, conduct standardized information disclosure and regular tracking of progress and targets, and establish multi-channel stakeholder engagement and dialogue mechanisms.

Building on the above consensus, we will pool wisdom and resources, engage in full collaboration, and establish a concrete action roadmap with the participation and support of multi-stakeholders to ensure the effective implementation of the GSSA Initiative.